Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748654 | 0.88 | HDAC2 (0.49) | ALDH1A1CA1CA2CA12TYR | |
| SCHEMBL5749467 | 0.80 | CA1 (0.66) | ALDH1A1CA1CA2CA12TYR | |
| SCHEMBL11371533 | 0.80 | TDP1 (0.48) | ALDH1A1TDP1CA1CA2CA12 | |
| SCHEMBL11375166 | 0.78 | GSK3B (0.56) | ALDH1A1CA1CA2HDAC3HDAC4 | |
| SCHEMBL28198345 | 0.78 | CA1 (0.44) | ALDH1A1TDP1CA1CA2CA12 | |
| SCHEMBL5454115 | 0.78 | PTGS2 (0.47) | TSHRALDH1A1TDP1CA1CA2 | |
| E-Methyl Cinnamate SCHEMBL1862419 | 0.78 | CA12 (0.69) | ALDH1A1CMA1GLATDP1CA1 | |
| E-Methyl Cinnamate SCHEMBL101530 | 0.78 | CA12 (0.69) | ALDH1A1CMA1GLATDP1CA1 | |
| E-Methyl Cinnamate SCHEMBL901224 | 0.78 | CA12 (0.69) | ALDH1A1CMA1GLATDP1CA1 | |
| E-Methyl Cinnamate SCHEMBL112062 | 0.78 | CA12 (0.69) | ALDH1A1CMA1GLATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-114716386-A | Novel exosome inhibitor and preparation method thereof | 北京和理咨询有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | claimed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | claimed |
| CN-107580596-B | Sulfimidoylpurine ketone compounds and derivatives for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | claimed |
| US-20200061225-A1 | ALDEHYDE SCAVENGER AND METHOD FOR REMOVING ALDEHYDES | TOSOH CORPORATION (JP) | 2020-02-27 | — | — | US | claimed |
| EP-3564334-A1 | ALDEHYDE SCAVENGER AND ALDEHYDE REMOVAL METHOD | Tosoh Corporation (JP) | 2019-11-06 | — | — | EP | claimed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | claimed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | claimed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| US-5461158-A | Immunodeficiency and autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-10-24 | — | — | US | claimed |
| EP-0639566-A1 | CYCLIC COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | claimed |
| WO-1994022840-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1994008977-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| EP-0279239-B1 | MICROBICIDES | CIBA-GEIGY AG (CH) | 1992-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | TSHR 4002/4885ALDH1A1 59/4885CMA1 3951/4885 |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | NQO1, UGT1A1, SULT1E1 | TSHR 4002/4885ALDH1A1 59/4885CMA1 3951/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | TSHR 3998/4885ALDH1A1 122/4885CMA1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.